Skip to content
CNS Clinical Research

Phoenix, Arizona

CNS clinical trials in Phoenix, AZ

46 CNS studies are recruiting participants at sites in Phoenix as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Phoenix at a glance

  • 46 studies are recruiting at a site in Phoenix.
  • By phase: Phase 1/2 (1), Phase 2 (12), Phase 3 (17), Phase 4 (2), No phase (4), Observational (10). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (35), university, hospital or other (10), government (1).
  • By research area: Depression (12), Epilepsy (10), Migraine (8), Parkinson's Disease (7), Multiple Sclerosis (5), Schizophrenia (4).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Phoenix

Basic details from each study's public record (the 30 most recently updated of 46). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    IMA Clinical Research Phoenix
    Registry record
    NCT07226661 · updated
  2. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Mayo Clinic Hospital in Arizona
    Registry record
    NCT06748222 · updated
  3. A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    NoesisPharma, LLC
    Registry record
    NCT07775300 · updated
  4. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tonix Pharmaceuticals, Inc.
    Registry record
    NCT07621237 · updated
  5. Study of ALTO-300 in MDD

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT05922878 · updated
  6. ALTO-207 in Adults With Treatment-resistant Depression (TRD)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT07553637 · updated
  7. A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Draig Therapeutics Ltd
    Study site
    Draig Clinical Site
    Registry record
    NCT07610473 · updated
  8. ALTO-100 in Bipolar Disorder With Depression (BD-D)

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT06656416 · updated
  9. Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Vanda Pharmaceuticals
    Study site
    Vanda Investigational Site
    Registry record
    NCT06830044 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Schizophrenia studies recruiting in Phoenix

  1. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT06887192 · updated
  2. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Southwest Autism Research and Resource Center
    Registry record
    NCT06229210 · updated
  3. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Banner Alzheimer's Institute
    Registry record
    NCT06585787 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Phoenix

  1. Deep Brain Stimulation (DBS) Retrospective Outcomes Study

    • Observational
    • All ages
    • All sexes
    Sponsor
    Boston Scientific Corporation
    Study site
    St. Joseph's Hospital & Medical Center
    Registry record
    NCT03664609 · updated
  2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic Cancer Center ( Site 0034)
    Registry record
    NCT06966700 · updated
  3. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Barrow Neurological Institute
    Registry record
    NCT07174310 · updated
  4. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic in Arizona - Phoenix ( Site 0147)
    Registry record
    NCT06170788 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Phoenix

  1. A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Study site
    Arizona Neuroscience Research, LLC
    Registry record
    NCT07299019 · updated
  2. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06433752 · updated
  3. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study sites
    AZ Integrated Neuro and Spine · Ctr for Neurology and Spine · Xenoscience Inc
    Registry record
    NCT07225504 · updated
  4. Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Sanofi
    Study site
    Center for Neurology and Spine - Phoenix - East Bell Road- Site Number : 8400195
    Registry record
    NCT07325292 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Epilepsy studies recruiting in Phoenix

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Xenoscience
    Registry record
    NCT05667142 · updated
  2. Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Neurona Therapeutics
    Study site
    Mayo Clinic Arizona Epilepsy Center
    Registry record
    NCT05135091 · updated
  3. Epilepsy Seizure Detection With Innovative Tripolar EEG (tEEG)

    • Observational
    • Ages 6 and older
    • All sexes
    Sponsor
    CREmedical
    Study site
    Barrow Neurological Institute Dignity Health dba St. Joseph's Hospital and Medical Center
    Registry record
    NCT05944692 · updated
  4. Diagnosing Epilepsy To EffeCT Change

    • No phase
    • Ages 18 to 75
    • All sexes
    Sponsor
    Epiminder America, Inc.
    Study site
    Mayo Clinic - Arizona
    Registry record
    NCT07110337 · updated
  5. Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

    • Observational
    • Ages 18 to 75
    • All sexes
    Sponsor
    Epiminder America, Inc.
    Study site
    Mayo Clinic - Arizona
    Registry record
    NCT07110454 · updated
  6. RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study sites
    Banner University Medical Center-Phoenix · Xenoscience
    Registry record
    NCT06798896 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Migraine studies recruiting in Phoenix

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Mayo Clinic Arizona
    Registry record
    NCT06972056 · updated
  2. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    IMA Clinical Research - Phoenix · Velocity Clinical Research, Phoenix
    Registry record
    NCT07816367 · updated
  3. Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Aspeya, Inc.
    Study site
    Arizona Research Center
    Registry record
    NCT07646613 · updated
  4. Responding With Evidence and Access for Childhood Headaches

    • No phase
    • Ages 10 to 17
    • All sexes
    Sponsor
    Children's Hospital Medical Center, Cincinnati
    Study site
    Phoenix Children's Hospital - Barrow Neurological Institute
    Registry record
    NCT05889624 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Ask about studies near Phoenix

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call